Literature DB >> 6450775

Suppressor T-lymphocyte deficiency in Graves' disease and Hashimoto's thyroiditis.

N Okita, V V Row, R Volpe.   

Abstract

The involvement of cell-mediated immunity in the pathogenesis of Graves' disease (GD) and Hashimoto's thyroiditis (HT) was investigated by employing a modified migration inhibition factor test using preparations of isolated T-lymphocytes. The migration of T-lymphocytes from patients with GD and HT in response to crude human thyroid antigen was significantly inhibited compared to the migration of T-lymphocytes from normal subjects. This response was organ specific. When normal T-lymphocytes were mixed with GD or HT T-lymphocytes in ratios varying from 1:9 to 1:1, the migration inhibition activity of the GD or HT T-lymphocytes in response to thyroid antigen was abolished, but was not abolished when two different GD or HT T-lymphocyte preparations were mixed. Mitomycin C inhibited this suppressive effect of normal T-lymphocytes in vitro, but did not influence the migration inhibition activity of the antigen-sensitized GD or HT T-lymphocytes. On the other hand, the migration inhibition of GD and HT T-lymphocytes was prevented by puromycin. There thus appears to be activity in normal T-lymphocytes which can suppress the ability of GD and HT T-lymphocytes to respond to the thyroid antigen, which is lacking in the GD and HT T-lymphocytes themselves. Our results are consistent with the hypothesis that there is a defect in suppressor T-lymphocyte function in GD and HT.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6450775     DOI: 10.1210/jcem-52-3-528

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Remission of Graves' disease with hyperthyroidism by a combination of glucocorticoids and antithyroid drugs.

Authors:  S A Peter
Journal:  J Natl Med Assoc       Date:  1991-03       Impact factor: 1.798

2.  Long-term immunological study in Graves' disease treated with thyroid arterial embolization.

Authors:  Wei Zhao; Bu-Lang Gao; Cang-Zheng Jin; Gen-Fa Yi; Hui-Ying Yang; Hong Li; Dian-Ping Song; Ji-Hong Hu; Yong-Neng Jiang
Journal:  J Clin Immunol       Date:  2008-07-17       Impact factor: 8.317

3.  Studies on the immunoregulation of thyroid autoantibody production in vitro.

Authors:  P Benveniste; V V Row; R Volpé
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

4.  Gluten specific suppressor T cell dysfunction in coeliac disease.

Authors:  G R Corazza; P Sarchielli; M Londei; M Frisoni; G Gasbarrini
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

5.  Immunological studies of autoimmune thyroid disorders: abnormalities in the inducer T cell subset and proliferative responses to autologous and allogeneic stimulation.

Authors:  C Fournier; H Chen; A Leger; J Charreire
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

6.  Anti-thyroid drugs and lymphocyte function. II. The in vivo effect on blastogenesis and suppressor cell activity in Graves' disease.

Authors:  N Goldrath; J Shoham; H Bank; Z Eisenstein
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

7.  Biological activity of lymphocytotoxic antibodies in Graves' disease and Hashimoto's thyroiditis.

Authors:  W Pruzanski; H Capes; R Baur; B E Wenzel; V V Row; R Volpé
Journal:  J Endocrinol Invest       Date:  1984-02       Impact factor: 4.256

8.  Analysis of T cell subsets in Graves' disease: alterations associated with carbimazole.

Authors:  M E Ludgate; A M McGregor; A P Weetman; S Ratanachaiyavong; J H Lazarus; R Hall; G W Middleton
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

9.  Thyroid function in mice with experimental autoimmune thyroiditis.

Authors:  A O Vladutiu; E M Kenney
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

10.  Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.

Authors:  J Charreire; G Karsenty; P Bouchard; G Schaison
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.